Skip to main content Accessibility help
×
Home
  • Print publication year: 2013
  • Online publication date: August 2013

Chapter 8 - Imaging and behavior in Parkinson’s disease: functional imaging

from Section 2 - Diagnosis and biomarkers

References

1. DuboisB, FeldmanHH, JacovaC, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734–46.
2. DuboisB, FeldmanHH, JacovaC, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurology 2010; 9: 1118–27.
3. McKhannGM, KnopmanDS, ChertkowH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 263–9.
4. HughesAJ, DanielSE, LeesAJ.Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease. Neurology 2001; 57: 1497–9.
5. JellingerKA, AttemsJ.Does striatal pathology distinguish Parkinson disease from dementia?Acta Neuropathol 2001; 102: 355–63.
6. AarslandD, PerryR, BrownA, LarsenJP, BallardC.Neuropathology of dementia in Parkinson’s disease: a prospective, community-based study. Ann Neurol 2005; 58: 773–6.
7. SilvermanDH, SmallGW, PhelpsME.Clinical value of neuroimaging in the diagnosis of dementia: sensitivity and specificity of regional metabolic and other parameters for early identification of Alzheimer’s disease. Clin Positron Imaging 1999; 2: 119–30.
8. HuangC, MattisP, PerrineK, et al. Metabolic abnormalities associated with mild cognitive impairment in Parkinson’s disease. Neurology 2008; 70: 1470–7.
9. YongSW, YoonJK, AnYS, LeeP.A comparison of cerebral glucose metabolism in Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies. Eur J Neurol 2007; 14: 1357–62.
10. Vander BorghtT, MinoshimaS, GiordaniB, et al. Cerebral metabolic differences in Parkinson’s and Alzheimer’s disease matched for dementia severity. J Nucl Med 1997; 38: 797–802.
11. HuM, Taylor-RobinsonSD, ChaudhuriKR, et al. Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. Brain 2000; 123: 340–52.
12. JokinenP, ScheininN, AaltoS, et al. [11C]PIB-, [18F]FDG-PET and MRI imaging in patients with Parkinson’s disease with and without dementia. Parkinsonism Relat Disord 2010; 16: 666–70.
13. HiranoS, EckertT, FlanaganMA, EidelbergD.Metabolic networks for assessment of therapy and diagnosis in Parkinson’s disease. Mov Disord 2009; 24 (Suppl 2): S725–31.
14. PolitoC, BertiV, RamatS, et al. Interaction of caudate dopamine depletion and brain metabolic changes with cognitive dysfunction in early Parkinson’s disease. Neurobiol Aging 2012; 206, e29–39.
15. BrooksDJ.Imaging approaches to Parkinson disease. J Nucl Med 2010; 51: 596–609.
16. BrooksDJ, PaveseN.Imaging non-motor aspects of Parkinson’s disease. Progr Brain Res 2010; 184: 205–18.
17. GilmanS, KoeppeRA, LittleR, et al. Differentiation of Alzheimer’s disease from dementia with Lewy bodies utilizing positron emission tomography with [18F] fluorodeoxyglucose and neuropsychological testing. Exp Neurol 2005; 191 (Suppl 1): S95–103.
18. MinoshimaS, FosterNL, SimaAA, et al. Alzheimer’s disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001; 50: 358–65.
19. PerneczkyR, DrzezgaA, BoeckerH, et al. Right prefrontal hypometabolism predicts delusions in dementia with Lewy bodies. Neurobiol Aging 2009; 30: 1420–9.
20. AlbinRL, MinoshimaS, D’AmatoCJ, et al. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disesase. Neurology 1996; 47: 462–6.
21. EckertT, TangC, EidelbergD.Assessment of the progression of Parkinson’s disease: a metabolic network approach. Lancet Neurol 2007; 6: 926–32.
22. HilkerR, ThomasAV, KleinJC, et al. Dementia in Parkinson’s disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005; 65: 1716–22.
23. HuXS, OkamuraN, AraiH, et al. 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia of Lewy bodies. Neurology 2000; 55: 1575–7.
24. ItoK, Nagano-SaitoA, KatoT, et al. Striatal and extrastriatal dysfunction in Parkinson’s disease with dementia: a 6-[18F]fluoro-L-dopa PET study. Brain 2002; 125; 1358–65.
25. MorrishPK, RakshiJS, BaileyDL, SawleGV, BrooksDJ.Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998; 64: 314–19.
26. WalkerZ, CostaDC, WalkerRW, et al. Differentiation of dementia with Lewy bodies from Alzheimer’s disease using dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002; 73: 134–40.
27. O’BrienJT, McKeithIG, WalkerZ, et al. Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Br J Psychiatry 2009; 194: 34–9.
28. BenamerTS, PattersonJ, GrossetDG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT imaging. The [123I] –FP-CIT Study Group. Mov Disord 2000; 15: 503–10.
29. RinneJO, BergmanJ, RuottinenH, et al. Striatal uptake of a novel PETl ligand [18F] beta-CFT, is reduced in early Parkinson’s disease. Synapse 1999; 31: 119–24.
30. TorstensonR, HartvigP, LångströmB, WesterbergG, TedroffJ.Differential effect of levodopa on dopaminergic function in early and advanced Parkinson’s disease. Ann Neurol 1997; 41: 334–40.
31. KoeppeRA, GilmanS, JunckL, WernetteK, FreyKA.Differentiating Alzheimer’s disease from dementia with Lewy bodies and Parkinson’s disease with (+)-[11C]dihydrotetrabenazine positron emission tomography. Alzheimers Dement 2008; 4: S67–76.
32. RinneJO, LaihinenA, RuottinenH, et al. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson’s disease: a PET study with [11C] raclopride. J Neurol Sci 1995; 132: 156–61.
33. TedroffJ, PedersenM, AquiloniusSM, et al. Levodopa-induced changes in synaptic dopamine in patients with Parkinson’s disease as measured by [11C] raclopride displacement and PET. Neurology 1996; 46: 1430–6.
34. TurjanskiN, LeesAJ, BrooksDJ.PET studies on striatal dopaminergic receptor binding in drug naive and L-dopa treated Parkinson’s disease patients with and without dyskinesia. Neurology 1997; 49: 717–23.
35. SteevesTD, MiyasakiJ, ZurowskiM, et al. Increased striatal dopamine release in parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 2009; 132: 1376–85.
36. RaoH, MamikonyanE, DetreJA, et al. Decreased ventral striatal activity with impulse control disorder in Parkinson’s disease. Mov Disord 2010; 25: 1660–9.
37. DoderM, RabinerEA, TurjanskiN, et al. Brain serotonin HT1A receptors in Parkinson’s disease with and without depression measured by positron emission tomography and 11C-WAY100635. Mov Disord 2000; 15 (Suppl 3): 213.
38. RemyP, DoderM, LeesA, TurjanskiN, BrooksD.Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005; 128: 1314–22.
39. BallangerB, StrafellaAP, van EimerenT, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 2010; 67: 416–21.
40. KuhlDE, MinoshimaS, FesslerJA, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer’s disease, and Parkinson’s disease. Ann Neurol 1996; 40: 399–410.
41. HilkerR, ThomasAV, KleinJC, et al. Dementia in Parkinson’s disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005; 65: 1716–22.
42. BohnenNI, KauferDI, HendricksonR.Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and Parkinson dementia. J Neurol 2006; 253: 242–7.
43. BohnenNI, MüllerML, KotagalV, et al. Heterogeneity of cholinergic denervation in Parkinson’s disease without dementia. J Cereb Blood Flow Metab 2012; 32: 1609–17.
44. KotagalV, AlbinRL, MüllerML, et al. Symptoms of rapid eye movement sleep behaviour disorder are associated with cholinergic denervation in Parkinson disease. Ann Neurol 2012; 71: 560–8.
45. AsahinaM, SuharaT, ShinotohH, et al. Brain muscarinic receptors in progressive supranuclear palsy and Parkinson’s disease: a positron emission tomography study. J Neurol Neurosurg Psychiatry 1998; 65: 155–63.
46. NordbergA, RinneJ, KadirA, LångströmB.The use of PET in Alzheimer’s disease. Nat Rev Neurol 2010; 6: 78–87.
47. KlunkWE, EnglerH, NordbergA, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol 2004; 55: 306–19.
48. SojkovaJ, ResnickSM.In vivo amyloid imaging. Curr Alzheimer Res 2011; 8: 366–72.
49. JohanssonA, SavitchevaI, ForsbergA, et al. [11C]-PIB imaging in patients with Parkinson’s disease: preliminary results. Parkinsonism Relat Disord 2008; 14: 345–7.
50. MaetzlerW, ReimboldM, LiepeltI, et al. [11C]PIB binding in Parkinson’s disease dementia. Neuroimage 2008; 39: 1027–33.
51. EdisonP, RoweCC, RinneJ, et al. Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008; 79: 1331–8.
52. GompertsSN, LocascioJJ, MarquieM, et al. Brain amyloid and cognition in Lewy body diseases. Mov Disord 2012; 27: 965–73.
53. MaetzlerW, Liepelt ReimoldM, et al. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 2009; 34: 107–12.
54. FosterER, CampbellMC, BurackMA, et al. Amyloid imaging of Lewy body-associated disorders. Mov Disord 2010; 25: 2516–23.
55. BurackMA, HartleinJ, FloresHP, et al. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 2010; 74: 77–84.
56. VillemagneVL, OngK, MulliganRS, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 2011; 52: 1210–17.
57. KalaitzakisME, GraeberMB, GentlemanSM, PearceRK.Striatal β-amyloid deposition in Parkinson disease with dementia. Neuropathol Exp Neurol 2008; 67: 155–61.
58. KaitzakisME, WallsAJ, PearceRK, GentelmanSM.Striatal Aβ peptide deposition mirrors dementia and differentiates DLB and PDD from other Parkinsonian syndromes. Neurobiol Dis 2011; 41: 377–84.
59. DuggerBN, SerranoGE, SueLI, et al. Presence of striatal amyloid plaques in Parkinson’s disease dementia predicts concomitant Alzheimer’s disease: usefulness for amyloid imaging. J Parkinsons Dis 2012; 2: 57–65.
60. KlunkWE, PriceJC, MathisCA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 2007; 27: 6174–84.
61. Graff-RadfordJ, BoeveBF, PedrazaO, et al. Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. Brain 2012; 135: 2470–7.
62. GompertsSN, LocascioJJ, MarquieM, et al. Brain amyloid and cognition in Lewy body disease. Mov Disord 2012; 27: 965–73.
63. OuchiY, YoshikawaE, SekineY, et al. Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol 2005; 57: 168–75.
64. GerhardA, PaveseN, HottonG, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis 2006; 21: 404–12.
65. CarterSF, SchollM, AlmkvistO, et al. Evidence for astrocytosis in Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multi-tracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med 2012; 53: 37–46.